Tumor Biology

, Volume 36, Issue 8, pp 5865–5871 | Cite as

Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer

  • Dong-Hoe Koo
  • Hee Jin Lee
  • Jin-Hee Ahn
  • Dok Hyun Yoon
  • Sung-Bae Kim
  • Gyungyub Gong
  • Byung Ho Son
  • Sei Hyun Ahn
  • Kyung Hae Jung
Research Article

Abstract

Trastuzumab (H)-based chemotherapy has been an active treatment in patients with HER2-positive breast cancer; however, primary and secondary resistance has occurred in patients treated with H alone or in combination with chemotherapy. Biomarkers were searched using tissue microarrays (TMA) in HER2-positive advanced breast cancer patients treated with H and paclitaxel (P) combination chemotherapy between October 2004 and August 2010. Tumor blocks were analyzed for Tau-protein, beta-III tubulin, PTEN, p27, IGF-1R, c-Met, CD44, and MUC4 by immunohistochemical (IHC) analysis. The correlation between IHC status and clinical outcomes, including response rate (RR), progression free survival (PFS), and overall survival (OS), was investigated. With a median follow-up duration of 54.1 months (range, 42.3–72.7 months), 65 patients received H + P chemotherapy. The overall RR was 63 % (95 % CI, 51–75 %), and seven patients (11 %) with high Tau/low PTEN expression showed a significantly lower RR (14 % vs. 69 %; p = 0.008). The odds ratio for a poor response was 13.3 (95 % CI, 1.5–119.0; p = 0.020). In addition, patients with high Tau/low PTEN showed a trend of poor survival in terms of PFS (6.6 months vs. 9.6 months, p = 0.052). Subsequent multivariate analysis showed that high Tau/low PTEN (hazard ratio [HR] 2.40, 95 % CI, 1.06–5.47; p = 0.037) was the poor prognostic factor independently associated with PFS after adjusting for possible confounding factors such as recurrence/metastasis, age, performance status, visceral metastasis, and hormone receptor status. High Tau-protein and low PTEN expression showed a significant association with poor response to H + P chemotherapy in patients with HER2-positive advanced breast cancer.

Keywords

Breast neoplasms Trastuzumab Paclitaxel Resistance Tau PTEN 

Notes

Conflicts of interest

None

References

  1. 1.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med. 2001;344:783–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the m77001 study group. J Clin Oncol. 2005;23:4265–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009;15:7479–91.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton. 2003;56:45–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule associated protein (map)-tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle. 2005;4:1149–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005;102:8315–20.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, et al. Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol. 2007;60:27–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, et al. Pten activity could be a predictive marker of trastuzumab efficacy in the treatment of erbb2-overexpressing breast cancer. Br J Cancer. 2006;94:247–52.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Takahashi S, Kamata Y, Tamo W, Koyanagi M, Hatanaka R, Yamada Y, et al. Relationship between postoperative recurrence and expression of cyclin e, p27, and ki-67 in non-small cell lung cancer without lymph node metastases. Int J Clin Oncol. 2002;7:0349–55.CrossRefGoogle Scholar
  11. 11.
    Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, et al. Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. Hum Pathol. 2004;35:1537–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol. 2002;20:1544–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Honeth G, Bendahl P-O, Ringner M, Saal L, Gruvberger-Saal S, Lovgren K, et al. The cd44+/cd24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Llinares K, Escande F, Aubert S, Buisine M-P, de Bolos C, Batra SK, et al. Diagnostic value of muc4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol. 2003;17:150–7.CrossRefGoogle Scholar
  15. 15.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.CrossRefGoogle Scholar
  16. 16.
    Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.CrossRefGoogle Scholar
  17. 17.
    Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for her-2-positive metastatic breast cancer. Oncologist. 2008;13:515–25.CrossRefPubMedGoogle Scholar
  18. 18.
    Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B, Szczylik C. The role of tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol. 2011;68:553–7.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Tanaka S, Nohara T, Iwamoto M, Sumiyoshi K, Kimura K, Takahashi Y, et al. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol. 2009;64:341–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res. 2007;13:2061–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M, Tanaka F, et al. Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer. 2006;94:1894–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shim BY, Kim CH, Ahn MI, Kim SW, Cho DG, Cho KD, et al. Her2 and tau expression as potential markers for response and survival to first line taxane plus cisplatin therapy in non-small cell lung cancer. Asia Pac J Clin Oncol. 2009;5:232–41.CrossRefGoogle Scholar
  23. 23.
    Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, et al. The pten/mmac1/tep tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene. 1999;18:7034–45.CrossRefPubMedGoogle Scholar
  24. 24.
    Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. Pten activation contributes to tumor inhibition by trastuzumab, and loss of pten predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–27.CrossRefPubMedGoogle Scholar
  25. 25.
    Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, et al. Pik3ca mutations, pten, and pher2 expression and impact on outcome in her2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol. 2012;23:2034–42.CrossRefPubMedGoogle Scholar
  26. 26.
    Razis E, Bobos M, Kotoula V, Eleftheraki A, Kalofonos H, Pavlakis K, et al. Evaluation of the association of pik3ca mutations and pten loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011;128:447–56.CrossRefPubMedGoogle Scholar
  27. 27.
    Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, et al. Pten, pik3ca, p-akt, and p-p70s6k status: association with trastuzumab response and survival in patients with her2-positive metastatic breast cancer. Am J Pathol. 2010;177:1647–56.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, et al. Impact of pten protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the north central cancer treatment group n9831 trial. J Clin Oncol. 2013;31:2115–22.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Guarneri V, Barbieri E, Conte P. Biomarkers predicting clinical benefit: fact or fiction? JNCI Monog. 2011;2011:63–6.CrossRefGoogle Scholar
  30. 30.
    Singer CF, Köstler WJ, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta. 2008;1786:105–13.PubMedGoogle Scholar
  31. 31.
    Zhang X, Li F, Bulloj A, Zhang Y-w, Tong G, Zhang Z. Tumor-suppressor pten affects tau phosphorylation, aggregation, and binding to microtubules. FASEB J. 2006;20:1272–4.CrossRefPubMedGoogle Scholar
  32. 32.
    Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.CrossRefPubMedGoogle Scholar
  33. 33.
    Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with erbb2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124–30.CrossRefPubMedGoogle Scholar
  34. 34.
    Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for her2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Dong-Hoe Koo
    • 1
    • 4
  • Hee Jin Lee
    • 2
  • Jin-Hee Ahn
    • 1
  • Dok Hyun Yoon
    • 1
  • Sung-Bae Kim
    • 1
  • Gyungyub Gong
    • 2
  • Byung Ho Son
    • 3
  • Sei Hyun Ahn
    • 3
  • Kyung Hae Jung
    • 1
  1. 1.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guKorea
  2. 2.Department of Pathology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  3. 3.Department of Surgery, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  4. 4.Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea

Personalised recommendations